Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | DNMT1 | P26358 | 5/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | POLG | P54098 | 1/20 | 0.40 |
| ▸ | DCK | P27707 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2580898 | 1.00 | ALB (0.55) | ALBDNMT1ADRB1POLGDCK | |
| SCHEMBL5717526 | 1.00 | ALB (0.55) | ALBDNMT1ADRB1POLGDCK | |
| SCHEMBL19657159 | 1.00 | ALB (0.55) | ALBDNMT1ADRB1POLGDCK | |
| SCHEMBL8621829 | 0.88 | ALB (0.55) | ALBDNMT1ADRB1POLGDCK | |
| SCHEMBL13871553 | 0.88 | ALB (0.55) | ALBDNMT1ADRB1POLGDCK | |
| SCHEMBL14577836 | 0.88 | ALB (0.55) | ALBDNMT1ADRB1POLGDCK | |
| SCHEMBL4129272 | 0.88 | ALB (0.55) | ALBDNMT1ADRB1POLGDCK | |
| SCHEMBL3195379 | 0.88 | ALB (0.55) | ALBDNMT1ADRB1POLGDCK | |
| SCHEMBL2583043 | 0.88 | DNMT1 (0.42) | ALBDNMT1ADRB1LMNASMN1; SMN2 | |
| SCHEMBL2583037 | 0.88 | DNMT1 (0.42) | ALBDNMT1ADRB1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | ISMAILI HICHAM MOULAY ALAOUI (CA) | 2004-12-09 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| EP-1296690-A2 | METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES | Shire Biochem Inc. (CA) | 2003-04-02 | — | — | EP | claimed |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | VIROCHEM PHARMA INC. (CA) | 2002-02-14 | — | — | US | claimed |
| WO-2001060315-A2 | METHOD FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS USING NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC. (CA) | 2001-08-23 | — | — | WO | claimed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | UNIV CALIFORNIA (US) | 2021-10-28 | — | — | US | disclosed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | disclosed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | disclosed |
| US-6784161-B2 | VIRICIDES FOR HEPATITIS C | BIOCHEM PHARMA, INC. (CA) | 2004-08-31 | — | — | US | disclosed |
| EP-1411954-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | Pharmasset Limited (BB) | 2004-04-28 | — | — | EP | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002032920-A2 | MODIFIED NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | PHARMASSET LIMITED (BB) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ALB 4137/4885DNMT1 570/4885ADRB1 3876/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | ALB 2637/4885DNMT1 402/4885ADRB1 4637/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | ALB 2637/4885DNMT1 402/4885ADRB1 4637/4885 |
| US-20040248844-A1 | Method for the treatment or prevention of Flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | ALB 1932/4885DNMT1 1551/4885ADRB1 3565/4885 |
| US-20020019363-A1 | Method for the treatment or prevention of flavivirus infections using nucleoside analogues | NUDT1, HAVCR2, SLC28A1 | ALB 1932/4885DNMT1 1551/4885ADRB1 3565/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | ALB 2637/4885DNMT1 402/4885ADRB1 4637/4885 |
| US-20210332070-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | ALB 2637/4885DNMT1 402/4885ADRB1 4637/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | ALB 4137/4885DNMT1 570/4885ADRB1 3876/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | ALB 3667/4885DNMT1 2832/4885ADRB1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.